Gold prices muted as investors eye Fed, inflation data    Egypt's c. bank offers EGP 50b in T-bills    Comera Financial Holding, Beltone Holding forge strategic partnership for Egypt's digital leap    Chimps learn and improve tool-using skills even as adults    13 Million Egyptians receive screenings for chronic, kidney diseases    Asian shares steady on solid China trade data    Al-Mashat invites Dutch firms to Egypt-EU investment conference in June    Trade Minister, Building Materials Chamber forge development path for Shaq El-Thu'ban region    Cairo mediation inches closer to Gaza ceasefire amidst tensions in Rafah    Taiwan's exports rise 4.3% in April Y-Y    Microsoft closes down Nigeria's Africa Development Centre    Global mobile banking malware surges 32% in 2023: Kaspersky    Mystery Group Claims Murder of Businessman With Alleged Israeli Ties    Microsoft to build $3.3b data centre in Wisconsin    Egypt, World Bank evaluate 'Managing Air Pollution, Climate Change in Greater Cairo' project    US Embassy in Cairo announces Egyptian-American musical fusion tour    Japanese Ambassador presents Certificate of Appreciation to renowned Opera singer Reda El-Wakil    Sweilam highlights Egypt's water needs, cooperation efforts during Baghdad Conference    AstraZeneca injects $50m in Egypt over four years    Egypt, AstraZeneca sign liver cancer MoU    Swiss freeze on Russian assets dwindles to $6.36b in '23    Amir Karara reflects on 'Beit Al-Rifai' success, aspires for future collaborations    Climate change risks 70% of global workforce – ILO    Prime Minister Madbouly reviews cooperation with South Sudan    Egypt retains top spot in CFA's MENA Research Challenge    Egyptian public, private sectors off on Apr 25 marking Sinai Liberation    Debt swaps could unlock $100b for climate action    President Al-Sisi embarks on new term with pledge for prosperity, democratic evolution    Amal Al Ghad Magazine congratulates President Sisi on new office term    Egyptian, Japanese Judo communities celebrate new coach at Tokyo's Embassy in Cairo    Uppingham Cairo and Rafa Nadal Academy Unite to Elevate Sports Education in Egypt with the Introduction of the "Rafa Nadal Tennis Program"    Financial literacy becomes extremely important – EGX official    Euro area annual inflation up to 2.9% – Eurostat    BYD، Brazil's Sigma Lithium JV likely    UNESCO celebrates World Arabic Language Day    Motaz Azaiza mural in Manchester tribute to Palestinian journalists    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Study links Prozac, Paxil use with birth defects
Antidepressants Prozac and Paxil fou to cause birth defects, Oloft, went off the hook
Published in Ahram Online on 13 - 07 - 2015

A sweeping government study of thousands of women has found links between the older antidepressants Prozac and Paxil and birth defects, but has cleared other popular treatments in the class, including Celexa, Lexapro and Pfizer's Zoloft, which is the subject of a major lawsuit over birth defect claims.
Earlier studies had raised questions about antidepressants in a class of drugs known as Selective Serotonin Reuptake Inhibitors or SSRIs, prompting the U.S. Food and Drug Administration in 2005 to issue a safety warning about use of the treatments during pregnancy.
In the current study, published in the British Medical Journal, researchers at the U.S. Centers for Disease Control and Prevention wanted to see if the birth defect risk affected the entire class of drugs, or only select treatments.
For the study, the researchers asked nearly 28,000 women if they took Celexa, Lexapro, Prozac, Paxil or Zoloft any time from one month before conception through the third month of pregnancy and analyzed which women bore children with birth defects.
They found that many popular antidepressants - Celexa, Lexapro or Zoloft - are not associated with birth defects. Only two in the study, Prozac, sold generically as fluoxetine, and Paxil, sold generically as paroxetine, were implicated.
In women who took those two drugs early in pregnancy, birth defects occurred 2 to 3.5 times more frequently compared with women who did not take them.
Prozac use was associated with a birth defect in which a baby's skull is misshapen. Paxil use was associated with a defect in which a baby's intestines protrude outside the body and with anencephaly, in which a baby is missing parts of the brain and skull, the study found.
Both Paxil and Prozac were linked to a heart defect.
The study's authors noted that the risks appeared to be small. For example, in women who took paroxetine early in pregnancy, the risk for anencephaly rose from 2 cases per 10,000 to 7 per 10 000.
The analysis was only able to show links between the drugs and birth defects, but could not prove that the drugs caused the deformities. The authors called the findings about Zoloft "reassuring" because the drug was used by some 40 percent of the women in the study who said they had used an antidepressant in early pregnancy.
http://english.ahram.org.eg/News/135323.aspx


Clic here to read the story from its source.